Novel Biomarker Identified for Two Different Cancers
|
By LabMedica International staff writers Posted on 17 Apr 2014 |
|
Image: Histopathology of laryngeal squamous cell carcinoma (Photo courtesy of Masaryk University).
A new biomarker linked to better outcomes for patients with head and neck cancers and non-small-cell lung cancer (NSCLC) has been identified.
The biomarker could help scientists develop new diagnostics and therapies and help physicians determine the best long-term treatments for patients with these cancers.
Scientists from the University of Pittsburgh (PA, USA) examined tumor samples from 187 patients with non-small-cell lung cancer and 60 patients with head and neck squamous cell carcinomas (HNSCC). The median follow-up for overall survival (OS) and disease-free survival (DFS) for NSCLC patients was 69.0 months and 35.9 months, respectively. The median follow-up for HNSCC patients was 41 months.
The team used antibody-based immunological techniques, cell cultures, immunoprecipitation, immunohistochemistry and in situ quantification. For tumor analysis, tissue microarrays of formalin-fixed and paraffin-embedded tumors and control tissues were used. Each tumor was represented by three distinct cores for NSCLC and two for HNSCC. The nuclear signal intensity was quantified by automated quantitative analysis for NSCLC and Aperio software for HNSCC (Aperio Technologies, Vista, CA, USA).
The investigators found that the expression of a protein called choline phosphate cytidylyltransferase-α CCT-α or CCTα, which acts as an “antigen” that prompts the immune system to produce antibodies against it. CCTα was associated with longer survival rates, including for patients with NSCLC who were treated with surgery alone, without the use of platinum-based chemotherapy drugs and associated toxic side effects.
Laura J. Niedernhofer, MD, PhD, an associate professor and a senior author of the study said, “Based on what we found, a high CCTα expression appears to be indicative of survival, making CCTα a promising biomarker. Our findings suggest that CCTα may, in fact, be more important in determining outcomes in patients with both types of cancer than the already established excision repair cross-complementation group 1 (ERCC1) protein.”
Related Links:
University of Pittsburgh
Aperio Technologies
The biomarker could help scientists develop new diagnostics and therapies and help physicians determine the best long-term treatments for patients with these cancers.
Scientists from the University of Pittsburgh (PA, USA) examined tumor samples from 187 patients with non-small-cell lung cancer and 60 patients with head and neck squamous cell carcinomas (HNSCC). The median follow-up for overall survival (OS) and disease-free survival (DFS) for NSCLC patients was 69.0 months and 35.9 months, respectively. The median follow-up for HNSCC patients was 41 months.
The team used antibody-based immunological techniques, cell cultures, immunoprecipitation, immunohistochemistry and in situ quantification. For tumor analysis, tissue microarrays of formalin-fixed and paraffin-embedded tumors and control tissues were used. Each tumor was represented by three distinct cores for NSCLC and two for HNSCC. The nuclear signal intensity was quantified by automated quantitative analysis for NSCLC and Aperio software for HNSCC (Aperio Technologies, Vista, CA, USA).
The investigators found that the expression of a protein called choline phosphate cytidylyltransferase-α CCT-α or CCTα, which acts as an “antigen” that prompts the immune system to produce antibodies against it. CCTα was associated with longer survival rates, including for patients with NSCLC who were treated with surgery alone, without the use of platinum-based chemotherapy drugs and associated toxic side effects.
Laura J. Niedernhofer, MD, PhD, an associate professor and a senior author of the study said, “Based on what we found, a high CCTα expression appears to be indicative of survival, making CCTα a promising biomarker. Our findings suggest that CCTα may, in fact, be more important in determining outcomes in patients with both types of cancer than the already established excision repair cross-complementation group 1 (ERCC1) protein.”
Related Links:
University of Pittsburgh
Aperio Technologies
Gold Member
Collection and Transport System
PurSafe Plus®
Automatic CLIA Analyzer
Shine i9000
Capillary Blood Collection Tube
IMPROMINI M3
Latest Pathology News
- AI Tool Predicts Chemotherapy Response from Biopsy Slides
- Sex Differences in Alzheimer’s Biomarkers Linked to Faster Cognitive Decline
- World’s First Optical Microneedle Device to Enable Blood-Sampling-Free Clinical Testing
- Novel mcPCR Technology to Transform Testing of Clinical Samples
- Pathogen-Agnostic Testing Reveals Hidden Respiratory Threats in Negative Samples
- Molecular Imaging to Reduce Need for Melanoma Biopsies
- Urine Specimen Collection System Improves Diagnostic Accuracy and Efficiency
- AI-Powered 3D Scanning System Speeds Cancer Screening
- Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples
- New AI-Driven Platform Standardizes Tuberculosis Smear Microscopy Workflow
- AI Tool Uses Blood Biomarkers to Predict Transplant Complications Before Symptoms Appear
- High-Resolution Cancer Virus Imaging Uncovers Potential Therapeutic Targets
- Research Consortium Harnesses AI and Spatial Biology to Advance Cancer Discovery
- AI Tool Helps See How Cells Work Together Inside Diseased Tissue
- AI-Powered Microscope Diagnoses Malaria in Blood Smears Within Minutes
- Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Channels
Clinical Chemistry
view channel
AI Sensor Detects Neurological Disorders Using Single Saliva Drop
Neurological disorders such as Parkinson’s disease and Alzheimer’s disease often develop gradually and present subtle symptoms in their early stages. Because early signs are frequently vague or atypical,... Read more
New Blood Test Index Offers Earlier Detection of Liver Scarring
Metabolic fatty liver disease is highly prevalent and often silent, yet it can progress to fibrosis, cirrhosis, and liver failure. Current first-line blood test scores frequently return indeterminate results,... Read more
Molecular Diagnostics
view channel
World’s First Portable POC Test Simultaneously Detects Four Common STIs in One Hour
Sexually transmitted infections (STIs) often present with similar symptoms, making accurate diagnosis challenging without laboratory testing. Delays in identifying the exact infection can lead to inappropriate... Read more
Simple One-Hour Saliva Test Detects Common Cancers
Early detection is critical for improving cancer outcomes, yet many diagnostic tests rely on invasive procedures such as blood draws or biopsies. Researchers are exploring simpler approaches that could... Read more
Hematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Microbiology
view channel
WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
Tuberculosis (TB) remains one of the world’s leading infectious disease killers, yet millions of cases go undiagnosed or are detected too late. Barriers such as reliance on sputum samples, limited laboratory... Read more
New Imaging Approach Could Help Predict Dangerous Gut Infection
Clostridioides difficile infections affect roughly half a million people in the United States each year and are a leading cause of infectious diarrhea in healthcare settings. The bacterium can trigger... Read more
Pathology
view channel
Novel mcPCR Technology to Transform Testing of Clinical Samples
DNA methylation is an important biological marker used in the diagnosis and monitoring of many diseases, including cancer. These chemical modifications to DNA influence gene activity and can reveal early... Read more
Sex Differences in Alzheimer’s Biomarkers Linked to Faster Cognitive Decline
Sex differences in Alzheimer’s disease present ongoing diagnostic challenges, with women often experiencing a disproportionate disease burden even when preclinical amyloid-beta levels are similar to men.... Read more
Technology
view channel
AI Model Outperforms Clinicians in Rare Disease Detection
Rare diseases affect an estimated 300 million people worldwide, yet diagnosis is often protracted and error-prone. Many conditions present with heterogeneous signs that overlap with common disorders, leading... Read more
AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
Periprosthetic joint infection (PJI) is a rare but serious complication affecting 1% to 2% of primary joint replacement surgeries. The condition occurs when bacteria or fungi infect tissues around an implanted... Read more
Industry
view channel
Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss
Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
WHX Labs in Dubai spotlights leadership skills shaping next-generation laboratories
WHX Labs in Dubai (formerly Medlab Middle East), held at Dubai World Trade Centre (DWTC) from 10–13 February, brings together international experts to discuss the factors redefining laboratory leadership,... Read more
